Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.

Int J Chron Obstruct Pulmon Dis · 2009 · PMC2802045 · PMID 20054436

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP = 0.07so close (0.05 < p ≤ 0.1)

16 In our study, the subgroup of patients with an initial FEV 1 35% to 65% of predicted showed a trend to benefit from augmentation therapy ( P = 0.07).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.